loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about DSSTox_CID_2897, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    DSSTox_CID_2897

    APIs // Active Pharmaceutical Ingredients

    DOSSIERs // Finished Dosage Forms

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    Also known as: 17598-65-1, Desacetyllanatoside c, Deacetyllanatoside c, Cedilanid-d, Deslanosidum, Deslanosido
    Molecular Formula
    C47H74O19
    Molecular Weight
    943.1  g/mol
    InChI Key
    OBATZBGFDSVCJD-LALPQLPRSA-N
    FDA UNII
    YGY317RK75
    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
    2.1.2 InChI
    InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
    2.1.3 InChI Key
    OBATZBGFDSVCJD-LALPQLPRSA-N
    2.1.4 Canonical SMILES
    CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CC(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC7CC(C(C(O7)C)OC8CC(C(C(O8)C)OC9C(C(C(C(O9)CO)O)O)O)O)O
    2.1.5 Isomeric SMILES
    C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O
    2.2 Other Identifiers
    2.2.1 UNII
    YGY317RK75
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cedilanid D

    2. Cedilanid-d

    3. Cedilanidd

    4. Desacetyl Lanatoside

    5. Desacetyldigilanide C

    6. Desacetyllanatoside C

    7. Deslanatoside C

    8. Lanatoside, Desacetyl

    2.3.2 Depositor-Supplied Synonyms

    1. 17598-65-1

    2. Desacetyllanatoside C

    3. Deacetyllanatoside C

    4. Cedilanid-d

    5. Deslanosidum

    6. Deslanosido

    7. Glucodigoxin

    8. Deslanosid

    9. Deacetylanatoside C

    10. Desacetyl-lanatoside C

    11. Desace

    12. Lanatoside C, Deacetyl-

    13. Ygy317rk75

    14. Sediranido

    15. Lekozid

    16. Chebi:31468

    17. Deslanosidum C

    18. Dsstox_cid_2897

    19. Dsstox_rid_76778

    20. Dsstox_gsid_22897

    21. (3beta,5beta,12beta)-3-{[beta-d-glucopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide

    22. Deslanosidum [inn-latin]

    23. Deslanosido [inn-spanish]

    24. Deacetyl-lanatoside C

    25. Cedilanid-d (tn)

    26. Cas-17598-65-1

    27. Einecs 241-568-1

    28. Brn 0078187

    29. Unii-ygy317rk75

    30. Cedilanide

    31. Deslanoside [usp:inn:ban:jan]

    32. Ncgc00159441-02

    33. Deslanoside [mi]

    34. Deslanoside [inn]

    35. Deslanoside [jan]

    36. Deslanoside [vandf]

    37. Chembl1614

    38. Deslanoside [mart.]

    39. Deslanoside [usp-rs]

    40. Deslanoside [who-dd]

    41. 3beta-(o-beta-d-glucopyranosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-o-beta-d-digitoxosyl-(1-4)-beta-d-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid

    42. 4-18-00-02455 (beilstein Handbook Reference)

    43. Card-20(22)-enolide, 3-((o-beta-d-glucopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-

    44. Schembl125311

    45. Gtpl6806

    46. Deslanoside (jp17/usp/inn)

    47. Dtxsid1022897

    48. Deslanoside [orange Book]

    49. Deslanoside [ep Monograph]

    50. Deslanoside [usp Impurity]

    51. Hy-a0154

    52. Tox21_111671

    53. Mfcd00135818

    54. Tox21_111671_1

    55. Zinc253668332

    56. Db01078

    57. Ncgc00159441-03

    58. 3-[(o-beta-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide

    59. 3beta-{[beta-d-glucopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide

    60. Card-20(22)-enolide, 3-((o-beta-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-

    61. Cs-0017480

    62. D01240

    63. E88575

    64. 598d651

    65. Q5264583

    66. (3beta,5beta,12beta)-3-{[beta-d-glucopyranosyl-(1-->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-2,6-dideoxy-beta-d-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide

    67. 3-[(o-beta-d-glucopyranosyl-(1-->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl-(1-->4)-o-2,6-dideoxy-beta-d-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide

    68. Card-20(22)-enolide, 3-((o-.beta.-d-glucopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-o-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-.beta.-d-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3.beta.,5.beta.,12.beta.)-

    2.4 Create Date
    2005-08-08
    3 Chemical and Physical Properties
    Molecular Weight 943.1 g/mol
    Molecular Formula C47H74O19
    XLogP3-0.3
    Hydrogen Bond Donor Count9
    Hydrogen Bond Acceptor Count19
    Rotatable Bond Count10
    Exact Mass942.48243013 g/mol
    Monoisotopic Mass942.48243013 g/mol
    Topological Polar Surface Area282 Ų
    Heavy Atom Count66
    Formal Charge0
    Complexity1760
    Isotope Atom Count0
    Defined Atom Stereocenter Count26
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Deslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.

    5.2 MeSH Pharmacological Classification

    Cardiotonic Agents

    Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)

    Anti-Arrhythmia Agents

    Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)

    Enzyme Inhibitors

    Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

    5.3 ATC Code

    C - Cardiovascular system

    C01 - Cardiac therapy

    C01A - Cardiac glycosides

    C01AA - Digitalis glycosides

    C01AA07 - Deslanoside

    5.4 Absorption, Distribution and Excretion

    Absorption

    Little absorption from the gastrointestinal tract (40%).

    5.5 Biological Half-Life

    36 hours

    5.6 Mechanism of Action

    Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

    Post Enquiry
    POST ENQUIRY